Gland Pharma Ltd
NSE:GLAND
Gross Margin
Gland Pharma Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Gland Pharma Ltd
NSE:GLAND
|
237.4B INR |
62%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
685.8B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.5B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196.2B CHF |
73%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
176.4B CHF |
75%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
81%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.9B GBP |
82%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
128.2B USD |
74%
|
Gland Pharma Ltd
Glance View
Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare. What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Gland Pharma Ltd's most recent financial statements, the company has Gross Margin of 61.6%.
You don't have any saved screeners yet